Seasonal Allergies: Pollen, Timing, and Year-Round Patterns in the US

Seasonal allergies affect an estimated 81 million people in the United States, according to the Asthma and Allergy Foundation of America (AAFA), making them one of the most prevalent chronic conditions in the country. This page examines the biological mechanisms driving seasonal allergic reactions, the specific pollen calendars that govern symptom onset across US climate regions, and the clinical boundaries that separate seasonal from perennial allergy presentations. Understanding these patterns helps patients and clinicians contextualize symptom timing, identify likely triggers, and navigate the broader regulatory and healthcare landscape surrounding allergy diagnosis and treatment.

Definition and scope

Seasonal allergies — classified clinically as a subset of allergic rhinitis — are IgE-mediated hypersensitivity reactions triggered by aeroallergens that appear in the environment at predictable, vegetation-driven intervals. Unlike food or drug sensitivities, seasonal allergens are airborne and inhaled rather than ingested or dermally absorbed.

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, classifies seasonal allergic rhinitis as distinct from perennial allergic rhinitis on the basis of exposure duration: seasonal presentations are temporally linked to specific pollination windows, whereas perennial presentations persist year-round due to indoor allergens such as dust mites, pet dander, or mold.

Three primary aeroallergen categories drive seasonal reactions in the US:

  1. Tree pollen — typically peaks February through May, varying by latitude and species
  2. Grass pollen — dominates May through July across most regions
  3. Weed pollen — peaks August through October, with ragweed (Ambrosia spp.) representing the dominant weed allergen

A single ragweed plant can release approximately 1 billion pollen grains over one season (AAFA, Ragweed Allergy), and ragweed pollen has been detected in the atmosphere up to 400 miles from the nearest plant source, illustrating the geographic scale of seasonal exposure. For a population-level view of how frequently these conditions present, the allergy statistics in the US page provides sourced prevalence data.

How it works

Seasonal allergic reactions follow a two-phase immunological sequence that the National Library of Medicine (NLM) describes as sensitization followed by elicitation.

Sensitization occurs during initial pollen exposure. Antigen-presenting cells process inhaled pollen proteins and stimulate B lymphocytes to produce allergen-specific immunoglobulin E (IgE) antibodies. These antibodies bind to mast cells lining the nasal mucosa and conjunctiva — a primed state that produces no symptoms but establishes immunological memory.

Elicitation occurs on subsequent exposures. Incoming pollen proteins cross-link the surface-bound IgE antibodies, triggering mast cell degranulation and rapid release of histamine, leukotrienes, and prostaglandins. This cascade produces the hallmark symptoms: nasal congestion, rhinorrhea, sneezing, and allergic conjunctivitis. A secondary late-phase reaction, driven by eosinophil recruitment, can sustain inflammation for 6–24 hours after initial allergen contact.

Pollen counts — measured in grains per cubic meter of air — are monitored and reported by the National Allergy Bureau (NAB), a program of the American Academy of Allergy, Asthma & Immunology (AAAAI). The NAB uses a standardized Rotorod or Burkard sampler protocol to collect and quantify airborne particles, enabling the regional pollen calendars that clinicians use to correlate symptom onset with exposure windows.

Common scenarios

Seasonal allergy presentations vary significantly by US geographic region and by individual sensitization profile. Four archetypal patterns account for the majority of clinical encounters:

Early-spring tree pollen reactors — Patients in the Mid-Atlantic and Southeast United States experience symptoms as early as February when juniper, cedar (Juniperus spp.), and elm trees begin pollinating. In the Pacific Northwest, alder (Alnus spp.) is the dominant early-season tree allergen, often peaking in January and February.

Late-spring grass pollen reactors — Timothy grass (Phleum pratense), Kentucky bluegrass (Poa pratensis), and Bermuda grass (Cynodon dactylon) drive late-spring symptoms across the Midwest, South, and California's Central Valley. Bermuda grass pollinates nearly year-round in southern Florida and coastal Texas, partially blurring the seasonal boundary in those subregions.

Fall ragweed reactors — Ragweed season is the single largest seasonal allergy burden nationally. The Centers for Disease Control and Prevention (CDC) notes that ragweed concentrations peak in mid-September across most of the continental US and extend through the first hard frost. Patients sensitized to ragweed frequently exhibit cross-reactive oral allergy syndrome to foods such as melons, bananas, and zucchini.

Multi-sensitized polysensitive patients — Approximately 30–40% of allergic rhinitis patients are sensitized to pollen from 3 or more botanical families (AAAAI Position Statement on Polysensitization), producing overlapping symptom windows that can span February through October in temperate US climates. These patients may be clinically misclassified as perennial sufferers unless structured allergy testing methods are used to delineate individual sensitization profiles.

Children represent a distinct subpopulation: the allergy-and-the-atopic-march pattern describes how early sensitization in pediatric patients frequently evolves from eczema to rhinitis to asthma. For specifics on pediatric presentation timing, allergies in children provides relevant clinical context.

Decision boundaries

Clinicians and diagnosticians face three primary classification decisions when evaluating seasonal allergy presentations:

Seasonal vs. perennial distinction
Symptom chronology is the primary differentiator. Seasonal allergic rhinitis symptoms that resolve within 2–4 weeks of a documented pollen season's end point toward a pollen-driven etiology. Symptoms persisting through winter months — when outdoor pollen counts fall to near zero — indicate perennial sensitization to indoor allergens such as dust mites or pet dander, or a mixed presentation requiring separate characterization of each allergen class.

Allergic vs. non-allergic rhinitis
Non-allergic rhinitis (vasomotor rhinitis) produces nasal symptoms without IgE-mediated mechanisms and therefore does not produce positive results on allergen-specific IgE testing or skin prick testing. The AAAAI Practice Parameters for Allergic Rhinitis recommend skin prick testing or serum-specific IgE measurement (allergy blood tests explained) to confirm an allergic mechanism before initiating immunotherapy.

Comorbid asthma threshold
Allergic asthma co-occurs with seasonal allergic rhinitis in a significant proportion of patients. The Global Initiative for Asthma (GINA) 2023 report recommends evaluation for lower airway involvement — including spirometry — in any patient presenting with moderate-to-severe seasonal rhinitis, given the shared inflammatory pathway between the upper and lower respiratory tracts. The allergy action plans framework provides structured guidance for patients managing both conditions concurrently.

The full range of management options — from antihistamines and nasal corticosteroids to allergy immunotherapy — is catalogued on the main allergy resource index, which organizes diagnostic and treatment pathways by condition type.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)